Orfadin and Ramipril drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Orfadin (nitisinone) and Ramipril (ramipril). Common drug interactions include lenticular opacities among females and amino acid level increased among males.

The phase IV clinical study analyzes what interactions people have when they take Orfadin and Ramipril. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Orfadin?

Orfadin has active ingredients of nitisinone. eHealthMe is studying from 968 Orfadin users. Check the latest studies of Orfadin.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.

On Jul, 16, 2026

22 people who take Orfadin and Ramipril together, and have interactions are studied.

What are the common drug interactions of Orfadin and Ramipril, by gender? *:

female:

Lenticular opacities (swelling and opacity of the entire lens)
Amino acid level decreased
Bone marrow disorder
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Drug ineffective
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Infection
Liver transplant
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Amino acid level increased

male:

Amino acid level increased
Lenticular opacities (swelling and opacity of the entire lens)
Meibomian gland dysfunction (dry eyes)
Visual impairment
Cataract cortical (it affects outer part of lens)
Cataract (clouding of the lens inside the eye)
Conjunctival oedema (conjunctival swelling)
Drowning (process of experiencing respiratory impairment from submersion/immersion in liquid)

What are the common drug interactions of Orfadin and Ramipril, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Bone marrow disorder
Liver transplant
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Amino acid level increased
Conjunctival oedema (conjunctival swelling)
Lenticular opacities (swelling and opacity of the entire lens)
Cataract (clouding of the lens inside the eye)
Drowning (process of experiencing respiratory impairment from submersion/immersion in liquid)

50-59:

n/a

60+:

Amino acid level increased
Lenticular opacities (swelling and opacity of the entire lens)
Infection
Meibomian gland dysfunction (dry eyes)
Visual impairment
Cataract cortical (it affects outer part of lens)
Cataract (clouding of the lens inside the eye)
Amino acid level decreased
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Drug ineffective

What are the existing conditions these people have? *

Alkaptonuria (black urine disease): 20 people, 90.91%
Tyrosinaemia (tyrosine metabolism resulting in liver and kidney disturbances and mental retardation): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Orfadin and Ramipril?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously